Faecal calprotectin levels in a high risk population for colorectal neoplasia

Gut

Volumn 46, Issue 6, 2000, Pages 795-800

  Kronborg, O ^g   Ugstad, M ^a   Fuglerud, P ^b   Johne, B ^a   Hardcastle, J ^c   Scholefield, J H ^c   Vellacott, K ^d   Moshakis, V ^e   Reynolds, J R ^f  

^a ALTANA PHARMA AG   (Germany)

^b PAREXEL INTERNATIONAL   (United States)

^c QUEEN S MEDICAL CENTRE   (United Kingdom)

^d ROYAL GWENT HOSPITAL   (United Kingdom)

^e GEORGE ELIOT HOSPITAL   (United Kingdom)

^f DERBY CITY GENERAL HOSPITAL   (United Kingdom)

^g ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Calprotectin; Colonoscopy; Colorectal cancer; Polyps; Screening; Tumour markers

Indexed keywords

CALPROTECTIN;

ADULT; AGED; ARTICLE; CANCER SCREENING; CLINICAL TRIAL; COLON ADENOMA; COLORECTAL CANCER; COLORECTAL TUMOR; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FECES ANALYSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYPECTOMY; PRIORITY JOURNAL; RECTUM ADENOMA; SCREENING TEST;

ADENOMA; ADOLESCENT; ADULT; AGED; COLORECTAL NEOPLASMS; FECES; HUMANS; LEUKOCYTE L1 ANTIGEN COMPLEX; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; NEURAL CELL ADHESION MOLECULES; RISK FACTORS; SENSITIVITY AND SPECIFICITY;

EID: 0034028401     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.46.6.795     Document Type: Article

References (22)

1. 1 Johne B, Fagerhol MK, Lyberg T, et al. Functional and clinical aspects of the myelomonocyte protein calprotectin. Mol Pathol 1997;50:113-23.
2. 2 Roseth AG, Fagerhol MK, Aadland E, et al. Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study. Scand J Gastroenterol 1992;27:793-8.
3. 3 Roseth AG, Kristinsson J, Fagerhol MK, et al. Faecal calprotectin: A novel test for the diagnosis of colorectal cancer? Scand J Gastroenterol 1993;28:1073-6.
4. 4 Kewenter J, Björk S, Haglind E, et al. Screening and rescreening for colorectal cancer. A controlled trial of faecal occult blood testing in 27,700 subjects. Cancer 1988; 62:645-51.
5. 5 St. John DJB, Young GP, Alexeyeff MA, et al. Evaluation of new occult blood tests for detection of colorectal neoplasia. Gastroenterology 1993;104:1661-8.
6. 6 Allison JE, Tekawa IS, Ransom LJ, et al. A comparison of faecal occult-blood tests for colorectal cancer screening. N Engl J Med 1996;334:155-9.
7. 7 Robinson MHE, Marks CG, Farrands PA, et al. Screening for colorectal cancer with an immunological faecal occult blood test: 2 year follow-up. Br J Surg 1996;83:500-1.
8. 8 Allison JE. Review article: Faecal occult blood testing for colorectal cancer. Aliment Pharmacol Ther 1998;12:1-10.
9. 9 Jahn H, Jørgensen OD, Kronborg O, et al. Can Hemoccult-II™ replace colonoscopy in surveillance after radical surgery for colorectal cancer and after polypectomy? Dis Colon Rectum 1992;35:253-6.
10. 10 Kronborg O, Kristensson J, Tøn HI, Fuglerud P, Johne B. Fecal calprotectin levels in colorectal cancer patients and high risk subjects; a comparison with a new method. Orlando, Florida: AGA/DDW, May 1999, abstract.
11. 11 O'Brien MJ, O'Keane JC, Zauber A, et al. Precursors of colorectal carcinoma. Biopsy and biologic markers. Cancer 1992;70:1317-27.
12. 12 Jørgensen OD, Kronborg O, Fenger C. The Funen adenoma follow-up study. Characteristics of patients and initial adenomas in relation to severe dysplasia. Scand J Gastroenterol 1993;28:239-43.
13. 13 Jørgensen OD, Kronborg O, Fenger C. The Funen adenoma follow-up study. Incidence and death of colorectal carcinoma in an adenoma surveillance program. Scand J Gastroenterol 1993;28:869-74.
14. 14 Robinson MHE, Kronborg O, Williams CB, et al. Faecal occult blood testing and colonoscopy in the surveillance of subjects at high risk of colorectal neoplasia. Br J Surg 1995; 82:318-20.
15. 15 Kristinsson J, Nygaard K, Armbruster C, et al. Faecal calprotectin levels in colorectal cancer, measured with a new simplified method. Abstract World Congresses of Gastroenterology Vienna. Digestion 1998;59;730.
16. 16 Gilbert JA, Ahlquist DA, Mahoney DW, et al. Faecal marker variability in colorectal cancer: calprotectin versus hemoglobin. Scand J Gastroenterol 1996;31:1001-5.
17. 17 Husebye E, Tøn H. Biological variation in faecal calprotectin concentration in patients submitted for colonoscopy. Abstract World Congresses of Gastroenterology Vienna. Digestion 1998;59:731.
18. 18 Kristinsson J, Roseth A, Fagerhol MK, et al. Fecal calprotectin concentration in patients with colorectal carcinoma. Dis Colon Rectum 1998;41:316-21.
19. 19 Swidsinski A, Khilkin M, Kerjaschki D, Schreiber S, Ortner M, Weber J, Lochs H. Association between intraepithelial Escherichia coli and colorectal cancer. Gastroenterology 1998;115:281-6.
20. 20 Dutta SK. Noninvasive detection of colorectal cancer by molecular tools: coming of age. Editorials Gastroenterol 1998;114:1333-4.
21. 21 Yamao T, Matsumura Y, Shimada Y, et al. Abnormal expression of CD44 variants in the exfoliated cells in the feces of patients with colorectal cancer. Gastroenterology 1998;114:1196-205.
22. 22 Nollau P, Wagener C. Detection of mutant alleles of tumour cells in stool: diagnostic value and perspectives of highly sensitive molecular methods for the early detection of colorectal cancer. In: Schmiegel W, Schölmerich J, eds. Colorectal cancer. Molecular mechanisms, premalignant state and its prevention. FALK Symposium vol 109. Dordrecht: Kluwer Academic Publishers, 1998:135-43.